Novartis receives FDA approval for Egaten for the treatment of fascioliasis, a neglected tropical disease
- Egaten is the only drug approved in the US for the treatment of people with fascioliasis and is currently the only treatment recommended by the WHO?
- Fascioliasis, commonly known as liver fluke infestation, is estimated to infect 2.4 million people globally[1]
- Novartis has been donating Egaten to the WHO since 2005, helping to treat around 2 million patients in more than 30 countries
- FDA approval reinforces the company's commitment to reduce the burden of neglected tropical diseases including fascioliasis, leprosy and malaria
# # #
Novartis Media Relations Central media line: +41 61 324 2200 E-mail:?media.relations@novartis.comEric Althoff Novartis Global Media Relations +41 61 324 7999 (direct) +41 79 593 4202 (mobile) eric.althoff@novartis.com | Katerina Kontzalis Novartis Communications +41 61 324 1631 (direct) +41 79 797 8393 (Mobile) katerina.kontzalis@novartis.com |
Central | North America | ||
Samir Shah | +41 61 324 7944 | Richard Pulik | +1 212 830 2448 |
Pierre-Michel Bringer | +41 61 324 1065 | Cory Twining | +1 212 830 2417 |
Thomas Hungerbuehler | +41 61 324 8425 | ||
Isabella Zinck | +41 61 324 7188 |